# Leadership, Planning and Evaluation

> **NIH NIH P30** · YALE UNIVERSITY · 2022 · $655,583

## Abstract

LEADERSHIP, PLANNING AND EVALUATION 
PROJECT SUMMARY/ABSTRACT 
Effective and proactive leadership, planning, and evaluation are essential to the success of Yale Cancer 
Center’s (YCC) mission. Leadership, Planning and Evaluation (LPE) activities are instrumental in supporting 
YCC’s goals of fostering the most impactful science, translating Yale science into ground-­breaking clinical 
advances, developing innovative public health and prevention strategies, training the next generation of 
leaders in cancer research and reducing the burden of cancer throughout our catchment area and beyond. 
YCC Director, Charles Fuchs, MD, MPH, has overall responsibility for LPE and works closely with Associate 
Director, Research Affairs, Robert Garofalo, PhD, who oversees the implementation and progress of the 
Strategic Plan and leads the Administrative team that provides the organizational and analytical support for 
LPE activities.  
Dr. Fuchs benefits from input from the YCC Leadership committees, including the Mini-­Cab and Executive 
Committee (EC), both of which he Chairs, and from the External Scientific Advisory Board (ESAB), the Internal 
Advisory Board (IAB), the Shared Resource Oversight Committee (SROC), Membership Committee and the 
Education and Training Committee (ETC). Together, the internal and external advisory, operational and 
leadership committees help to maximize YCC’s success by providing in-­depth evaluation and thorough, expert 
direction for all basic, translational, clinical, and population-­based programmatic areas, shared resources, 
center administration, and the essential characteristics of an NCI Designated Cancer Center. 
Based on recommendations from internal and external advisory groups, the YCC Director and Senior 
Leadership have developed an innovative and comprehensive Strategic Plan to set the course for YCC over 
the next three to five years. Outcomes of planning and evaluation activities over the last funding period 
included numerous strategic and operational decisions made by Senior Leadership, as represented in the 
Director’s Mini-­Cabinet (Mini-­Cab) and Executive Committee, during the funding period that advanced multiple 
aspects of our plan to propel the Center’s mission forward. These include: increasing translational activity in all 
Research Programs through new internal grant programs;; key recruitments and collaborations;; developing the 
Translational Immuno-­Oncology Laboratory (TIL);; reorganizing our Biostatistics Shared Resource;; establishing 
the Translational Research Core Committee charged with developing infrastructure to enhance research 
access to clinical genomic information and biospecimens;; recruitment of Cancer Biology Institute faculty and 
physician-­scientists;; generating new institutional support to enhance key shared resource initiatives;; 
reorganizing Clinical Trials Office procedures to improve activation times;; launching the Diversity and Health 
Equity (D&HE) team to promote co...

## Key facts

- **NIH application ID:** 10461907
- **Project number:** 5P30CA016359-43
- **Recipient organization:** YALE UNIVERSITY
- **Principal Investigator:** CHARLES S FUCHS
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $655,583
- **Award type:** 5
- **Project period:** 1997-07-01 → 2024-07-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10461907

## Citation

> US National Institutes of Health, RePORTER application 10461907, Leadership, Planning and Evaluation (5P30CA016359-43). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/10461907. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*